270 related articles for article (PubMed ID: 33293372)
21. CD46 targeted
Li J; Huang T; Hua J; Wang Q; Su Y; Chen P; Bidlingmaier S; Li A; Xie Z; Bidkar AP; Shen S; Shi W; Seo Y; Flavell RR; Gioeli D; Dreicer R; Li H; Liu B; He J
J Exp Clin Cancer Res; 2023 Mar; 42(1):61. PubMed ID: 36906664
[TBL] [Abstract][Full Text] [Related]
22. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody.
Tsai WK; Zettlitz KA; Tavaré R; Kobayashi N; Reiter RE; Wu AM
Theranostics; 2018; 8(21):5903-5914. PubMed ID: 30613270
[TBL] [Abstract][Full Text] [Related]
23. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.
Knowles SM; Zettlitz KA; Tavaré R; Rochefort MM; Salazar FB; Stout DB; Yazaki PJ; Reiter RE; Wu AM
J Nucl Med; 2014 Mar; 55(3):452-9. PubMed ID: 24504052
[TBL] [Abstract][Full Text] [Related]
24. Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates.
Sarrett SM; Rodriguez C; Rymarczyk G; Hosny MM; Keinänen O; Delaney S; Thau S; Krantz BA; Zeglis BM
Bioconjug Chem; 2022 Sep; 33(9):1750-1760. PubMed ID: 35946495
[TBL] [Abstract][Full Text] [Related]
25. Detecting TRA-1-60 in Cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent.
White JM; Kuda-Wedagedara AN; Wicker MN; Spratt DE; Schopperle WM; Heath E; Viola NT
Mol Pharm; 2020 Apr; 17(4):1139-1147. PubMed ID: 32069422
[TBL] [Abstract][Full Text] [Related]
26.
Benedetto R; Massicano AVF; Crenshaw BK; Oliveira R; Reis RM; Araújo EB; Lapi SE
Cancer Biother Radiopharm; 2019 Jun; 34(5):288-296. PubMed ID: 30865493
[No Abstract] [Full Text] [Related]
27. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
28. A radiopharmaceutical [
Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N
Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708
[TBL] [Abstract][Full Text] [Related]
29.
Fung K; Vivier D; Keinänen O; Sarbisheh EK; Price EW; Zeglis BM
Molecules; 2020 May; 25(10):. PubMed ID: 32429033
[TBL] [Abstract][Full Text] [Related]
30. Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.
Glumac PM; Gallant JP; Shapovalova M; Li Y; Murugan P; Gupta S; Coleman IM; Nelson PS; Dehm SM; LeBeau AM
Clin Cancer Res; 2020 Mar; 26(5):1054-1064. PubMed ID: 31732520
[TBL] [Abstract][Full Text] [Related]
31. Molecular Design of
Morath V; Brandt C; Deuschle FC; Mendler CT; Blechert B; Summer D; Barinka C; Decristoforo C; Weber WA; Schwaiger M; Skerra A
Mol Pharm; 2023 May; 20(5):2490-2501. PubMed ID: 37068305
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a Radio-IMmunoStimulant (RIMS) in a Syngeneic Model of Murine Prostate Cancer and ImmunoPET Analysis of T-cell Distribution.
Śmiłowicz D; Schlyer D; Boros E; Meimetis L
Mol Pharm; 2022 Sep; 19(9):3217-3227. PubMed ID: 35895995
[TBL] [Abstract][Full Text] [Related]
33. ImmunoPET Imaging of Pancreatic Tumors with
Sobol NB; Korsen JA; Younes A; Edwards KJ; Lewis JS
Mol Imaging Biol; 2021 Feb; 23(1):84-94. PubMed ID: 32909244
[TBL] [Abstract][Full Text] [Related]
34. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.
Holland JP; Caldas-Lopes E; Divilov V; Longo VA; Taldone T; Zatorska D; Chiosis G; Lewis JS
PLoS One; 2010 Jan; 5(1):e8859. PubMed ID: 20111600
[TBL] [Abstract][Full Text] [Related]
35. Novel multifunctional
Kwon YD; Lee JY; La MT; Lee SJ; Lee SH; Park JH; Kim HK
Eur J Med Chem; 2020 Mar; 189():112099. PubMed ID: 32014792
[TBL] [Abstract][Full Text] [Related]
36. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule.
Cai H; Shi Q; Tang Y; Chen L; Chen Y; Tao Z; Yang H; Xie F; Wu X; Liu N; Yang Y; Wu H; Tian R; Lu X; Li L
Mol Pharm; 2019 May; 16(5):1950-1957. PubMed ID: 30986347
[TBL] [Abstract][Full Text] [Related]
37. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
38. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
39. A generic
Li N; Yu Z; Pham TT; Blower PJ; Yan R
Int J Nanomedicine; 2017; 12():3281-3294. PubMed ID: 28458546
[TBL] [Abstract][Full Text] [Related]
40. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for
Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
